Biosyn Research Chemicals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-06-2024
- Paid Up Capital ₹ 4.50 M
as on 16-06-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 64.70 M
as on 16-06-2024
- Satisfied Charges ₹ 9.83 M
as on 16-06-2024
- Revenue 15.85%
(FY 2022)
- Profit 105.23%
(FY 2022)
- Ebitda 645.01%
(FY 2022)
- Net Worth 7.74%
(FY 2022)
- Total Assets 2.72%
(FY 2022)
About Biosyn Research Chemicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹6.47 Cr. The company has closed loans amounting to ₹9.83 M, as per Ministry of Corporate Affairs (MCA) records.
Roja Gangavarapu and Ravi Gangavarapu serve as directors at the Company.
- CIN/LLPIN
U24100TG2008PTC059406
- Company No.
059406
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Biosyn Research Chemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Gangavarapu  | Managing Director | 29-May-2008 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Roja Gangavarapu | Additional Director | 22-Aug-2012 | Current |
Financial Performance and Corporate Structure Insights of Biosyn Research Chemicals.
Biosyn Research Chemicals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 15.85% increase. The company also saw a substantial improvement in profitability, with a 105.23% increase in profit. The company's net worth moved up by a moderate rise of 7.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biosyn Research Chemicals?
In 2022, Biosyn Research Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Oct 2023 | ₹3.00 Cr | Open |
Others Creation Date: 30 Jul 2020 | ₹1.80 M | Open |
Others Creation Date: 30 Apr 2020 | ₹0.90 M | Open |
How Many Employees Work at Biosyn Research Chemicals?
Unlock and access historical data on people associated with Biosyn Research Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biosyn Research Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biosyn Research Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
